REFERENCE · RECOVERY TECHNIQUE

Discussing an SSRI or SNRI With Your Prescriber

When this may fit: When medication is being considered for persistent dizziness or a coexisting condition and the benefits, risks and follow-up need to be clear. [Used in clinical practice; PPPD-specific placebo-controlled evidence uncertain]

For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources —

For the Person With FND

Being offered an antidepressant for dizziness can be confusing, particularly if nobody explains the reason. You are entitled to know what symptom the medicine is intended to help, how the decision was reached and what will happen if it does not suit you.

What do SSRI and SNRI mean?

SSRIs are selective serotonin reuptake inhibitors. SNRIs are serotonin–noradrenaline reuptake inhibitors. These medicines affect chemical signalling in the nervous system and are used for several conditions. Their name does not mean that a person offered one for dizziness must be depressed, or that PPPD is a proven chemical deficiency. [2][3]

Clinicians sometimes discuss them for PPPD or for an accompanying condition. The reason should be specific. Treating anxiety, depression, pain or migraine is not the same evidence question as treating PPPD itself.

What is known about benefit?

The 2023 Cochrane review found no eligible placebo- or no-treatment-controlled SSRI/SNRI trials under its PPPD criteria. That leaves uncertainty about benefit and harms for PPPD; it does not prove that a medicine cannot help. It is also a finding about that review and its search date, not a claim that no relevant research could ever appear. [1]

Make the decision with a clear plan

Ask what the medication is intended to change and what improvement would be meaningful to you.
Review current medicines, supplements, previous reactions and relevant medical conditions with the prescriber or pharmacist.
Ask which side effects to expect, which need prompt help, when review will occur and how long a fair trial might take for the chosen indication.
Agree how to change or stop treatment if needed. Request an accessible written plan rather than relying on memory.

Possible effects include nausea, sleep changes, dizziness, sweating and sexual side effects; the pattern and risks differ between medicines and people. New symptoms after a change should be discussed rather than automatically called a PPPD flare. Severe reactions or suicidal thoughts need urgent help. [2]

Stopping needs a plan too

Do not stop abruptly, change doses or alternate days using this page. Withdrawal can include dizziness and other symptoms and may be difficult to distinguish from the original condition. A prescriber should tailor a gradual reduction where appropriate, and adjust it to your response. If a dose is missed, seek the instructions for that particular medicine rather than guessing. [2]

Choosing not to start, or finding that adverse effects outweigh benefit, does not mean you have rejected recovery. Rehabilitation, accommodations and treatment of other conditions can still be discussed.

During a familiar flare

Follow the prescribed schedule and contact the treating team if the pattern changes. Extra doses are not a general rescue treatment for a dizzy spell. Record relevant missed doses or changes when asking for advice.

When to stop and seek assessment

Stop unsafe activity. Sudden or distinctly different dizziness with new weakness, double vision, speech trouble, inability to walk, severe headache, fainting or chest pain needs urgent assessment. Sudden hearing loss, head injury or persistent vomiting also needs prompt medical attention. Increasing falls or progressive loss of function warrants reassessment. Existing PPPD does not explain every new symptom. See the diagnostic and differential-assessment page.

For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources —

For Family, Friends, and Other Supporters

Respect the person’s decision and privacy. With consent, help keep the medicine instructions and review date accessible. Do not suggest an extra dose, abrupt withdrawal or a shared prescription. If the person reports a difficult reaction, help them contact a clinician rather than persuading them to endure it.

During a familiar flare, follow the agreed support and safety plan. Ask before taking over. New or substantially different symptoms need their own assessment; an exercise should never delay that care.

For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources —

For Clinicians and the Care Team

Use shared decision-making with a specific indication, realistic outcome and review interval. Distinguish practice-based PPPD prescribing from stronger evidence for an independently diagnosed comorbidity. Review interactions, activation, mood risk, falls, cardiovascular considerations and other drug-specific precautions. Explain discontinuation symptoms and a personalized stopping plan before treatment; response does not confirm PPPD or psychological causation.

Agree an accessible next step and review point. Consider meaningful activity, safety, access, effort and delayed effects alongside dizziness severity. Limited improvement is not grounds to withdraw assistance or infer lack of effort.

For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources —

Research and Sources

This page expands original entry 12, SSRI or SNRI discussion. Examples and practical prompts are educational adaptations, not patient quotations or a reproduced treatment protocol. Original-entry numbering does not imply thirteen independently validated treatments.

The Cochrane finding concerns strict modern PPPD criteria and an appropriate control, not every antidepressant or dizziness study. General NHS safety information supports the discussion of adverse effects and withdrawal. This page supplies no dose or taper schedule and does not claim medication is either required or ineffective.

Citation	Source	What it supports and its limits	Figure
1	FND-CIT-0039 — Webster KE, Harrington-Benton NA, Judd O, et al. Pharmacological interventions for persistent postural-perceptual dizziness (PPPD). Cochrane Database of Systematic Reviews. 2023;3:CD015188. DOI.	No eligible SSRI/SNRI placebo/no-treatment trials under its criteria; historical review, not proof of no benefit.	—
2	FND-CIT-0195 — NHS. Antidepressants. Patient information. Accessed September 22, 2026.	General medicine safety and withdrawal information; not PPPD efficacy evidence.	—
3	FND-CIT-0196 — Neurosymptoms.org. Functional Dizziness (PPPD). Specialist patient information. Accessed September 22, 2026.	Specialist explanation and treatment context; not a controlled treatment trial.	—

Sources checked: September 22, 2026 · Vestibular, neurological, lived-experience and accessibility review pending

For the Person With FND
For Family, Friends, and Other Supporters
For Clinicians and the Care Team
Research and Sources —